跳至主要内容
临床试验/NCT00398099
NCT00398099已完成3 期

Clinical Evaluation for the Efficacy, Safety, Tolerability & Medical Resource Utilization of Invanz (Ertapenem Sodium) Therapy

Merck Sharp & Dohme LLC0 个研究点目标入组 30 人开始时间: 2005年7月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
30
主要终点
Signs and symptoms of infection on days 3, 4, 7 and 14 during treatment

研究概览

简要总结

To collect clinical response data with the use of ertapenem in approved indications.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients, 20 years of age or older
  • Patients did not receive any systemic antibiotic before enrollment, or patients with failed clinical response (no improvement on symptoms or laboratory data) through previous antibiotic treatment
  • Patients who required therapy prior to identification of cause of infection

排除标准

  • Patient has a concomitant infection that may interfere with the evaluation of the response to ertapenem
  • Patient has an apache ii >
  • Patient has an infection caused by pathogens resistant to ertapenem
  • Patients with known allergy to ertapenem or other drugs in the same carbapenem class, beta - lactams, lidocaine or local anesthetics of the amide type
  • The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)

结局指标

主要结局

Signs and symptoms of infection on days 3, 4, 7 and 14 during treatment

次要结局

  • Safety and Tolerability

研究者

申办方类型
Industry
责任方
Sponsor

相似试验